Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial Save

Date Added
May 28th, 2019
PRO Number
Pro00087983
Researcher
Timothy Whelan

List of Studies


Profiles_link
Keywords
Lung, Pulmonary
Summary

The purpose of this study is to test the effects of the study drug, RVT-1601, in research subjects with persistent cough due to idiopathic pulmonary fibrosis (IPF) in improving cough (frequency and severity) and quality of life. RVT-1601 is delivered as a mist through an eFlow® nebulizer that research subjects will inhale through a mouthpiece attached to the nebulizer. The Screening period will last up to 4 weeks, in order to give the study doctor time to determine if you qualify for the study. After the Screening Period, you will participate in the study for approximately 24 weeks (6 months). Your total study participation is expected to be 28 weeks (7 months).

Institution
MUSC
Recruitment Contact
Abbi Reed
(843) 792-1820
reedab@musc.edu

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. Save

Date Added
April 9th, 2019
PRO Number
Pro00075953
Researcher
Timothy Whelan

List of Studies


Profiles_link
Keywords
Lung, Pulmonary
Summary

The main purpose of this study is to investigate how well GLPG1690, an experimental drug being investigated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), is tolerated and to see how well GLPG1690 works together with your current treatment of pirfenidone or nintedanib. Approximately 750 participants will take part in the study. It has been described that patients with IPF have increased levels of autotaxin which leads to inflammation of the lungs. It is being investigated whether GLPG1690 can, by decreasing the activity of autotaxin, reduce safely the inflammation in the lungs that occurs in people with IPF, and therefore affect the progression of the disease.

Institution
MUSC
Recruitment Contact
Abbi Reed
(843) 792-1820
reedab@musc.edu

A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis Save

Date Added
November 14th, 2017
PRO Number
Pro00070979
Researcher
Timothy Whelan

List of Studies


Profiles_link
Keywords
Lung, Pulmonary
Summary

The purpose of this study is to test an experimental drug called CC-90001. This study will test CC-90001 (at doses of either 200 mg or 400 mg, given by mouth, once daily) compared to placebo, an inactive substance that contains no medicine. This study is being conducted to test the effect of CC-90001 on improving your IPF, and to see how well your body tolerates CC-90001.

Institution
MUSC
Recruitment Contact
Tomika Caldwell
(843) 792-3162
caldwet@musc.edu

A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Save

Date Added
May 10th, 2016
PRO Number
Pro00054206
Researcher
Timothy Whelan

List of Studies


Profiles_link
Keywords
Drug Studies, Lung, Pulmonary
Summary

This research study includes adults (18 years of age or older) with Idiopathic Pulmonary Fibrosis (IPF). The study is being conducted to find out if KD025 is a safe and effective treatment. Participants will be put on the study drug, KD025, for about 24 weeks (followed by another 24 weeks on KD025 if tolerated well). They will be on a daily dose of 400mg (by mouth) and in previous tests have shown to reduce IPF and inflammation.

Institution
MUSC
Recruitment Contact
Ashley Warden
843-792-4349
jonesash@musc.edu

Change_preferences

-- OR --

Create_login